

Bimekizumab for treating moderate to severe hidradenitis suppurativa (terminated appraisal)

Technology appraisal guidance
Published: 15 January 2025

www.nice.org.uk/guidance/ta1028

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of bimekizumab for treating moderate to severe hidradenitis suppurativa in adults. This is because UCB Pharma withdrew from the appraisal. UCB Pharma could not agree an economically sustainable route to reimbursement for this additional indication.

Information

If NHS organisations wish to consider bimekizumab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-6729-2